Skip to main content
Equibles
RCUS logo

RCUS · Arcus Biosciences, Inc.

Track RCUS — free

Use RCUS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about RCUS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$29.21 -1.38 (-4.51%) At close · Aug 28
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$3.75B
Shares
127.33M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$29.21 Open$30.13 Day$29.06–30.44 52W close$10.59–31.57 Avg vol 30d1.2M Short int13.8M · 10.9% float · 12.3d Short vol72% Last earningsAug 5, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 5, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 5, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 14.4 · calm Equity put/call 0.62
      Technical
      price trend
      Strong Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +20%
      above
      Price vs 50-day avg +1%
      above
      RSI (14) 49
      neutral
      MACD trend Positive
      52-week position 89%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +4%
      trailing
      6-month return +25%
      trailing
      YTD return +23%
      this year
      Relative strength +11%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $29 › 200d $24 — 50d above 200d
      Institutional flow Accumulating
      +9% holders QoQ · +46 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      10.88% of float · ▲ +5.6% MoM · 12.3 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      232 holders — near 3-yr high, broad support
      Squeeze score 72
      high risk · 0–100
      Fundamentals
      Weak
      Revenue growth −4%
      Y/Y
      EPS growth −5%
      Y/Y
      Free cash flow $-484.0M
      Balance sheet $123.0M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 62%
      annualized · 1-yr
      Max drawdown −28%
      past year
      ATR 4.5%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Aug 5, 2026
      year-end 2026
      Cash, cash equivalents and marketable securities $600M
      full year 2026
      GAAP revenue GAAP Raised $65M – $75M
      May 5, 2026 $50M – $65M changed to Aug 5, 2026 $65M – $75M
      prior FY $247M midpoint −71.7% Y/Y
      Prior guidance period ended · from the 8-K filed Oct 28, 2025
      GAAP revenue · full year 2025 $225M – $235M
      Guided vs delivered · last 1 settled
      GAAP revenue full year 2025
      guided $225M – $235M
      $247M Beat +7.4%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Buy
      0 · 3 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +20% Bullish
      Price vs 50-day avg
      +1% Bullish
      RSI (14)
      49 Neutral
      MACD trend
      Positive Bullish
      52-week position
      89% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $29 › 200d $24 — 50d above 200d
      Institutional flow Accumulating
      +9% holders QoQ · +46 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      10.88% of float · ▲ +5.6% MoM · 12.3 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      232 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $11 Now $29 · 89% Range high $32
      vs 200-day avg +20% vs 50-day avg +1%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Cash, cash equivalents and marketable securities $775M as of June 30, 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      RCUS
      Arcus Biosciences, Inc.
      this stock
      		$3.75B +22.6% -4.3% — 10.9%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $137.30B +19.5% +46.2% 31.6 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $81.27B +2.9% +20.8% 19.6 2.3%
      ARGX
      Argenx SE
      		 $63.63B +21.7% — — 1.9%
      CSLLY
      Csl Ltd
      		 $59.23B — — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      232
      % held
      96.6%
      Net QoQ
      +3.4M sh
      Top holder
      GILEAD SCIENCES, INC.
      Held Float
      View
      Held by Funds
      Fund positions
      277
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      13.8M
      Days to cover
      12.3d
      Change
      +730.6K sh
      View
      Short Volume
      Short vol %
      72%
      As of
      Aug 28, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      92.1K
      Value
      $2.5M
      As of
      Jul 29, 2026
      View
      Off-Exchange
      Off-exchange %
      43.2%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $247.0M
      Net income (FY)
      $-353.0M
      EPS diluted
      $-3.29
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 5, 2026
      This year
      12
      View
      Proposed Sales
      Value
      $83.5K
      Shares
      2.8K
      Filed
      Aug 21, 2026
      View
      Earnings & Events
      Earnings Calls Upcoming
      Next call
      Sep 9, 2026
      Last call
      Aug 5, 2026
      View
      Investor Relations
      Latest news
      Arcus Biosciences to Participate…
      Published
      Aug 26, 2026
      Upcoming events
      3
      View

      Performance

      5D 20D 120D MTD YTD
      RCUS -3.7% +3.6% +24.7% +3.6% +22.6%
      SPY +0.5% +3.0% +13.4% +3.0% +12.8%
      vs SPY -4.2% +0.6% +11.2% +0.6% +9.8%
      Key facts CIK 1724521 CUSIP 03969F109 13F (30d) 199 filings 197 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)